Overview

Endotis Pharma ("Endotis" or "The Company"), founded in 2003, is a biopharmaceutical company that is developing high value, differentiated cardiovascular therapeutics based on validated targets and modes of action. Endotis focuses on niche areas of high unmet medical need where strong pharmaco-economic drivers support premium price

The Company portfolio includes

. a first-in-class neutralizable anticoagulant for the management of cardiopulmonary bypass during cardiac surgery
. an oral version of fondaparinux (Arixtra), a reference injectable marketed drug for the prevention and treatment of venous thromboembolism , and
. an oral antidotable anticoagulant for stroke prevention in atrial fibrillation

The Company products have issued or pending patents covering their use worldwide until 2025 and beyond

Based in Paris, Endotis is privately held and backed by leading international investors, including Sofinnova Partners, The Wellcome Trust, Endeavour Vision, Daiwa Bank and SMBC Bank. The senior management has extensive experience in the development, registration and marketing of pharmaceutical products in small and large companies